The development of new treatments for pancreatic cancer is set to be transformed by a £10m investment by Cancer Research UK into a network of clinical trials, aiming to find the right trial for the right patient.
The UK’s only current trial dedicated to the treatment of myelomonocytic leukaemia (CMML) has recruited its first patient. The Phase II MONOCLE study has opened at the Institute of Cancer & Genetics at Cardiff University, and has received funding support from the Cardiff ECMC.
A Phase I-II study supported by UCL ECMC has found that rucaparib can be used in the treatment of patients with high-grade ovarian cancer.
This study was the first to fully evaluate single-agent oral rucaparib, a PARP inhibitor, in patients with advanced solid tumors who had already undergone significant treatment for their cancer.
Welsh patients are to be some of the first in the world to access the drug-radiation combination trial, known as PARADIGM 2. The trial is co-funded by Cancer Research UK and The Brain Tumour Charity, and is part of CRUK’s ECMC Combinations Alliance and will be run at Velindre Cancer Centre by Dr James Powell.
From Monday 10 April, Dr Ilaria Mirabile of the ECMC Programme Office is taking on a new role as Network Lead.
As we enter the new five year funding period, Ilaria says that she is thrilled to be taking on the promotion, and is excited about the opportunities that lie ahead for the Network as a whole.
This year the ECMC Junior Investigators Network Group (JING) hosted its hugely successfully JING: Training the Next Generation residential in Glasgow. Now in its fifth year, the two-day meeting saw over 90 Network members come together to share their knowledge and experience in running early-phase clinical trials.
Researchers at Manchester and ICR ECMCs have found that tumour necrosis in patients with bladder cancer does not affect how they respond to drugs used in combination with radiotherapy. This may mean that a drug and radiotherapy combination can be used in bladder cancer treatment, regardless of necrosis state.